Corsera - Science & Technology

SCIENCE &
TECHNOLOGY

KLOTHO ▶

Klotho was one of the ancient Greek Fates. She essentially determined the healthy lifespan of individual mortals by spinning the thread of life. Corsera Health is developing a precision health tool called Klotho, a proprietary AI-enabled tool to predict lifetime risk of cardiovascular disease and the opportunity to extend healthspan. Beginning at any age and spanning any time period, Klotho can assess an individual’s lifetime risk of cardiovascular disease and quantify the benefit of lowering LDL cholesterol and blood pressure to extend cardiovascular healthspan.

PREVENTIVE RNAi MEDICINES ▶

High blood pressure and high LDL cholesterol are major drivers of cardiovascular disease and leading causes of global morbidity and mortality. Yet in current practice, treatment often begins only after these conditions have already developed. By then, years of exposure to disease-causing proteins may have caused irreversible harm, significantly increasing the short-term risk of cardiac events—damage that earlier intervention could have helped prevent. (ESC Congress 2025)

Treating these conditions typically requires multiple daily medications or frequent injections, creating a significant treatment burden.

At Corsera Health, our product development is powered by a robust scientific discovery engine enabling the development of preventive RNAi medicines. These are highly potent and specific siRNA molecules designed to be made at scale efficiently, and to silence the genes that drive these conditions. These include targets such as proprotein convertase subtilisin/kexin type 9 (PCSK9) and angiotensinogen (AGT)—both of which play critical roles in the insidious onset and progression of cardiovascular disease.

The development of these molecules is central to our prevention strategy, which integrates our predictive analytics with a once-annual dual-targeting intervention.

PROGRAMS ▶

Corsera Health’s once-annual, dual-targeting preventive RNAi medicine program is advancing rapidly and aims to address the most important drivers of cardiovascular disease mortality and morbidity.

Our lead pipeline program is a product formulation that harnesses the RNAi pathway with a once-annual subcutaneous injection to reduce levels of PCSK9 and AGT.

A Phase 1 clinical trial with COR-1004, a novel investigational siRNA targeting PCSK9, is ongoing. COR-1004 is the first of two components in the company’s lead preventive RNAi medicine program. A Phase 1 trial with COR-2003, a novel investigational siRNA targeting AGT, is anticipated to begin in mid-2026.

Encouraging preclinical data have been observed to date, including enhanced potency, improved safety and specificity profiles, robust knockdown and confirmed efficacy. Corsera Health has the commitment and potential to establish an entirely new paradigm for cardiovascular health and, for the first time, make cardiovascular disease prevention a reality.

SCALABLE SOLUTIONS ▶

Corsera Health’s innovative evidence generation and manufacturing approaches are rooted in principles of efficiency, scalability, and proactive multi-stakeholder collaboration.

We are building a lean infrastructure and leveraging a team with extensive experience in conducting efficient global clinical trials in cardiovascular disease. Our commitment to transparent and productive engagements with regulators and other key stakeholders ensures alignment and paves a streamlined path to commercialization.

We partner with leading manufacturing organizations to achieve the scale and efficiency needed to supply a large global market with potentially life-changing therapies.

MEANINGFUL IMPACT ▶

Cardiovascular disease – atherosclerotic cardiovascular disease (ASCVD) in particular – is currently projected to remain the leading cause of death for decades to come.

To drive meaningful impact, preventive RNAi medicines must be broadly accessible and affordable in what we believe will become an increasingly consumer-centric approach to disease prevention and management. We aim to empower individuals to understand, predict and prevent cardiovascular disease for themselves and their families.

Corsera Health unites innovation, impact, and accessibility. We expect to transform the future of cardiovascular health.